The 12 analysts offering 12-month price forecasts for Horizon Therapeutics PLC have a median target of 120.00, with a high estimate of 125.00 and a low estimate of 88.00. The median estimate represents a +31.19% increase from the last price of 91.47.
The current consensus among 12 polled investment analysts is to Buy stock in Horizon Therapeutics PLC. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.16
Reporting Date May 05
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.